MassIVE MSV000096324

Complete Public PXD057613

Enhancing the bothropic antivenom through a reverse antivenomics approach

Subscribe Comment Convert Spectra Reanalyze Spectra Compare Results Add Reanalysis

Description

Antivenoms are the only effective treatment for snakebite envenomation and have saved countless lives over more than a century. Despite its value, antivenoms often present risks of adverse reactions. Current formulations contain a substantial fraction of non-specific antibodies and serum proteins that do not neutralize venom toxins. While new alternatives are being researched and promising candidates emerge as the next generation of antivenoms, it remains clear that animal-derived antivenoms will still play a critical role for years to come. And current antivenom formulations could still be optimized for safety and efficacy. In this study, we used a reverse antivenomics approach to improve the bothropic antivenom (BAv), capturing toxin-specific antibodies through affinity chromatography using Bothrops jararaca venom toxins immobilized on CNBr-activated resin. This process produced an improved antivenom formulation (iBAv) enriched in neutralizing antibodies and depleted of serum protein contaminants. Proteomic analysis showed that iBAv was 87% depleted in albumin and 37-83% lower in other serum proteins compared to the original BAv. Functional assessments demonstrated that iBAv had a 2.9-fold higher affinity for B. jararaca venom toxins via surface plasmon resonance and a 2.8-fold lower ED50 in vivo in a mice model, indicating enhanced potency and efficacy. Our findings suggest that enriching specific neutralizing antibodies while depleting serum proteins may reduce the overall protein dose required and potentially decrease the risk of adverse reactions. Although technical and economic considerations remain for large-scale implementation, this affinity-enriched antivenom formulation represents a significant advancement in enhancing antivenom efficacy against Bothrops jararaca envenomations. [doi:10.25345/C56T0H76W] [dataset license: CC0 1.0 Universal (CC0 1.0)]

Keywords: antivenom ; reverse antivenomics ; affinity chromatography ; DatasetType:Proteomics

Contact

Principal Investigators:
(in alphabetical order) 		Alexandre Keiji Tashima, Escola Paulista de Medicina/UNIFESP, Brasil
Submitting User: aktashima

Publications

Chiarelli T, Hayashi JY, Galizio NDC, Casimiro FMS, Torquato R, Tanaka AS, Morais-Zani K, Tanaka-Azevedo AM, Tashima AK.
Enhancing the Bothropic Antivenom through a Reverse Antivenomics Approach.
J Proteome Res. Epub 2025 Jan 21.

Number of Files:
Total Size:
Spectra:
Subscribers:
 
Owner Reanalyses
Experimental Design
    Conditions:
    Biological Replicates:
    Technical Replicates:
 
Identification Results
    Proteins (Human, Remapped):
    Proteins (Reported):
    Peptides:
    Variant Peptides:
    PSMs:
 
Quantification Results
    Differential Proteins:
    Quantified Proteins:
 
Browse Dataset Files Browse Results
 
FTP Download Link (click to copy):

Species

Instrument

Modifications

- Dataset Reanalyses

+ Dataset History

Click here to queue conversion of this dataset's submitted spectrum files to open formats (e.g. mzML). This process may take some time.

When complete, the converted files will be available in the "ccms_peak" subdirectory of the dataset's FTP space (accessible via the "FTP Download" link to the right).
Number of distinct conditions across all analyses (original submission and reanalyses) associated with this dataset.

Distinct condition labels are counted across all files submitted in the "Metadata" category having a "Condition" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct biological replicates across all analyses (original submission and reanalyses) associated with this dataset.

Distinct replicate labels are counted across all files submitted in the "Metadata" category having a "BioReplicate" or "Replicate" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct technical replicates across all analyses (original submission and reanalyses) associated with this dataset.

The technical replicate count is defined as the maximum number of times any one distinct combination of condition and biological replicate was analyzed across all files submitted in the "Metadata" category. In the case of fractionated experiments, only the first fraction is considered.

"N/A" means no results of this type were submitted.
Originally identified proteins that were automatically remapped by MassIVE to proteins in the SwissProt human reference database.

"N/A" means no results of this type were submitted.
Number of distinct protein accessions reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct unmodified peptide sequences reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct peptide sequences (including modified variants or peptidoforms) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Total number of peptide-spectrum matches (i.e. spectrum identifications) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins quantified across all analyses (original submission and reanalyses) associated with this dataset.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins found to be differentially abundant in at least one comparison across all analyses (original submission and reanalyses) associated with this dataset.

A protein is differentially abundant if its change in abundance across conditions is found to be statistically significant with an adjusted p-value <= 0.05 and lists no issues associated with statistical tests for differential abundance.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
This dataset may not contain all raw spectra data as originally deposited in PRIDE. It has been imported to MassIVE for reanalysis purposes, so its spectra data here may consist solely of processed peak lists suitable for reanalysis with most software.